Close

Publications

Evaluating the impact of heterogeneity of prevalence and incidence in malaria cluster randomised control trials: Can trials be designed more efficiently?.
BIGGS, J; Challenger, J; Hellewell, J; Churcher, T; COOK, J;
2022
(2022).
GREENWOOD, B; SCHELLENBERG, D;
2022
Diseases (Basel, Switzerland), (2022).10 4 10.3390/diseases10040101.
KOSITZ, C; Drammeh, M; VASILEVA, H; Houghton, J; Ashall, J; D'ALESSANDRO, U; MARKS, M; BRADLEY, J;
2022
International Journal of Infectious Diseases (IJID), (2022).125, 10.1016/j.ijid.2022.10.043.
Chen, IT-T; Swai, JK; Msellemu, D; Lobo, NF; BRADLEY, J; Moore, SJ;
2022
Cochrane Database of Systematic Reviews, (2022).2022 11 10.1002/14651858.cd015128.
GOVOETCHAN, R; Oss, R; Sovi, A; Akogbto, M;
2022
International Journal of Mosquito Research, (2022).9 6 10.22271/23487941.2022.v9.i6b.653.
BESHIR, KB; Muwanguzi, J; Nader, J; MANSUKHANI, R; Traore, A; Gamougam, K; Ceesay, S; Bazie, T; Kolie, F; Lamine, MM; CAIRNS, M; SNELL, P; SCOTT, S; Diallo, A; Merle, CS; NDiaye, JL; Razafindralambo, L; Moroso, D; Ouedraogo, J-B; Zongo, I; Kessely, H; Doumagoum, D; BOJANG, K; Ceesay, S; Loua, K; ... SUTHERLAND, CJ.
2022
The Lancet Infectious diseases, (2022).23 3 10.1016/S1473-3099(22)00593-X.
Overall and gender-specific effects of intermittent preventive treatment of malaria with artemisinin-based combination therapies among schoolchildren in Mali: a three-group open label randomized controlled trial.
Maiga, H; OPONDO, C; CHICO, RM; Cohee, LM; Sagara, I; Djimde, A;
2022
American Journal of Tropical Medicine and Hygiene, (2022).107 4
Prevalence of sulfadoxine-pyrimethamine resistance markers of Plasmodium falciparum among pregnant women in an area of high malaria transmission: Nchelenge, Zambia.
Chaponda, M; Mwanza, S; Hachizovu, S; Nambozi, M; Gwasupika, J; Chaponda, EB; CHANDRAMOHAN, D; CHICO, RM;
2022
(2022).(4) 1422 107
Overall and gender-specific effects of intermittent preventive treatment of malaria with artemisinin-based combination therapies among schoolchildren in Mali: a three-group open label randomized controlled trial.
Maiga, H; OPONDO, C; CHICO, RM; Cohee, LM; Sagara, I; Djimde, A;
2022
(2022).(4) 0901 107